NIAID Launches Study of Vaccine to Prevent EBV
NIAID has launched an early-stage clinical trial to evaluate an investigational preventive vaccine for Epstein-Barr virus (EBV).
IVIG May Reverse Symptoms of Down Syndrome Regression Disorder
A new study shows treatment with IVIG shows promise for children and young adults with Down syndrome regression disorder (DSRD).
Combination COVID-19 and Influenza Vaccine Under Development
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.
Lyme Disease Vaccine Advances to Phase III Study
New data from a Phase II clinical trial of Valneva SE and Pfizer Inc.’s Lyme disease vaccine candidate, VLA15, shows it produced strong immune responses, prompting preparations for a Phase III study in the third quarter of 2022.
NIH Launches Study to Evaluate Three mRNA Vaccines for HIV
NIAID has launched a Phase I clinical trial evaluating three experimental HIV vaccines based on a mRNA platform — a technology used in several approved COVID-19 vaccines.
First Human Clinical Trial of Cancer Killing Virus Has Begun
A clinical trial of the Vaxina (the CF33-hNIS virus) designed to kill cancer cells has begun.
Flu Vaccines Poor Match to Influenza Strains This Season
According to CDC, this season’s influenza (flu) vaccines offered meager protection against mild cases of influenza.
FDA Approves New Gene Therapy Treatment for Rare Blood Disorder
FDA has given fast track approval for Bluebird Bio’s Zynteglo, a treatment designed to tackle the rare condition known as transfusion-dependent beta-thalassemia (TDBT).
New Program Launched to Identify Autoimmune Disease Therapies
A cross-disciplinary coalition of experts from academic centers across the United States is partnering with NIH, FDA, pharmaceutical companies and nonprofit organizations to identify new targets for therapies for autoimmune-meditated diseases.
Intranasal Flu Vaccine Developed with Nanoparticles
Researchers in a study funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health have developed an influenza (flu) vaccine administered through the nose that has been constructed with nanoparticles and offers stronger protection.